Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why
Longeveron shares fell 59% after hours after its ELPIS II trial missed its primary endpoint.
Share
Why It Matters
Longeveron's medicine test did not work as hoped. When a company's main medical test fails, people often lose faith in it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.